What biomarker tests are recommended for Bladder Cancer

Biomarker Testing for Bladder Cancer

The biomarker tests recommended for you depend on what stage of bladder cancer you have. Let me break down the different approaches:

For Non-Muscle-Invasive Bladder Cancer (NMIBC)

Early-stage cancer confined to the bladder lining

According to the NCCN Guidelines (Version 2.2025), biomarkers have a limited role in initial evaluation and management of early-stage disease. The primary diagnostic tools are:

• Cystoscopy (camera examination of the bladder)
• TURBT (transurethral resection of bladder tumor - a procedure to remove the tumor)
• Bimanual examination under anesthesia (EUA)

Currently, there is no routine role for urine cytology or urinary biomarkers in low-risk NMIBC. However, biomarkers may be considered if you have abnormal findings during cystoscopy or abnormal urine cytology results—your urologist will use their clinical judgment here.

For Locally Advanced or Metastatic Bladder Cancer (Stages IVA and IVB)

Cancer that has spread beyond the bladder or to distant sites

This is where biomarker testing becomes essential. According to NCCN Guidelines, you should receive somatic tumor testing (testing of the cancer cells themselves) at the time of initial diagnosis. This testing should include:

Key Biomarkers to Test:

1. FGFR3 Alterations

• What it is: A genetic change in the FGFR3 gene that some bladder cancers have
• Why it matters: If present, you may be eligible for targeted therapy with erdafitinib (an FDA-approved drug that specifically targets FGFR3 mutations)
• Clinical significance: This is a predictive biomarker—meaning it helps determine which treatments will work best for YOUR specific cancer

2. HER2 Status (by Immunohistochemistry/IHC)

• What it is: A protein called HER2 that appears on some cancer cells
• Why it matters: HER2-positive bladder cancer may respond to fam-trastuzumab deruxtecan (an FDA-approved antibody-drug conjugate)
• How it's tested: Pathologists examine your tumor tissue under a microscope using special stains

3. Microsatellite Instability (MSI-H) and Mismatch Repair (MMR) Status

• What it is: These tests look for defects in the cancer cell's DNA repair machinery
• Why it matters: MSI-H/MMR-deficient cancers may respond better to immunotherapy (checkpoint inhibitors)
• Clinical significance: Helps predict which patients benefit from immune-based treatments

4. PD-L1 Testing

• What it is: A protein that helps cancer cells hide from the immune system
• Why it matters: For patients who cannot receive cisplatin (a standard chemotherapy), PD-L1 testing helps determine if checkpoint inhibitor monotherapy (like atezolizumab) might be appropriate as first-line treatment

Testing Recommendations:

According to NCCN Guidelines:

• Testing should be done in CLIA-certified laboratories (Clinical Laboratory Improvement Amendments—this ensures quality standards)
• A larger genomic panel may be preferred to identify rare mutations that might have approved therapies or allow clinical trial eligibility
• Testing should be done early at diagnosis to facilitate treatment decisions and prevent delays in therapy

About Circulating Tumor DNA (ctDNA)

You may hear about blood tests that look for circulating tumor DNA (cancer DNA floating in your bloodstream). According to NCCN Guidelines:

• These ultrasensitive tests may have prognostic value (meaning they might predict outcomes)
• However, there are insufficient data to use ctDNA results alone to determine surveillance or therapy after surgery
• Studies show ctDNA can track response to therapy, but there's not enough evidence that changing treatment based on ctDNA results significantly improves outcomes

Questions to Ask Your Oncologist:

1. What stage is my bladder cancer, and which biomarker tests do you recommend for me?
2. Have my tumor samples been tested for FGFR3, HER2, MSI-H/MMR, and PD-L1?
3. If I have specific biomarker mutations, what treatment options does that open up for me?
4. Are there any clinical trials I might be eligible for based on my biomarker results?
5. Will you use a comprehensive genomic panel, or just targeted testing?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines Version 2.2025 - Bladder Cancer